8-K
filed May 15, 2024, 7:59 PM ET
ticker SNDX
CIK 0001395937
leadership
confidence high
sentiment positive
materiality 0.55
Syndax appoints Aleksandra Rizo to Board; Morrison resigns; annual meeting votes passed
Syndax Pharmaceuticals Inc
- Aleksandra Rizo, M.D., Ph.D., elected to Board effective May 15, replacing Briggs Morrison who resigned.
- Dr. Rizo receives $45,644 annual cash for Board service, $8,558 for Science & Technology Committee, plus initial option for 35,000 shares vesting monthly over three years.
- Annual meeting results: all director nominees elected (Huber 61.9M for, Jarrett 39.5M for), executive compensation advisory vote passed (46.2M for, 16.3M against), auditor ratified (65.4M for).
- Dr. Rizo is President/CEO of Vividion, brings hematology clinical development and regulatory experience.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Aleksandra Rizo was elected as Director at Syndax Pharmaceuticals Inc.
- Action
- elected
- Role
- Director
Exact text from the filing
On May 15, 2024, the Board of Directors (the “ Board ”) of Syndax Pharmaceuticals, Inc. (the “ Company ”), unanimously voted to elect Aleksandra Rizo, M.D., Ph.D. to the Board, effectively immediately
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Briggs W. Morrison resigned as Director at Syndax Pharmaceuticals Inc.
- Action
- resigned
- Role
- Director
Exact text from the filing
On May 14, 2024, Briggs W. Morrison, M.D. advised the Board that he will resign from his position as a Class III member of our Board effective immediately.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Syndax Pharmaceuticals Inc shareholders approved Election of directors at the 2024-05-15 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2024-05-15
Exact text from the filing
Proposal 1 : Election of directors: Nominee For Withheld Broker Non-Votes Martin H. Huber, M.D. 61,876,711 736,625 3,032,770
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Syndax Pharmaceuticals Inc shareholders approved Advisory vote on executive compensation at the 2024-05-15 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2024-05-15
Exact text from the filing
Proposal 2 : Advisory vote on executive compensation: For Against Abstain Broker Non-Votes 46,228,421 16,304,796 80,119 3,032,770
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Syndax Pharmaceuticals Inc shareholders approved Ratification of selection of independent registered public accounting firm at the 2024-05-15 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2024-05-15
Exact text from the filing
Proposal 3 : Ratification of selection of independent registered public accounting firm: For Against Abstain Broker Non-Votes 65,371,337 253,270 21,499 —
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.